Evidence map›Paper›PMID 42469812›Full record

ArticleJournal of nanobiotechnology2026

Membrane-coated Prussian blue nanocomplex with enhanced enzyme-mimic activity alleviates senile osteoporosis by reducing osteoprogenitor cell senescence and macrophage inflammation.

Yihan Lin, Yuyi Tian, Hao Liu, Jian Yuan, Luhong Dai, Xiaona He, Shang Zhu, Xintian Xu, Bin Liu, Lihong Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yihan LinDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yuyi TianSchool of Medicine, Xiantao Vocational College, Xiantao, 433000, Hubei Province, China.
Hao LiuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jian YuanDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Luhong DaiDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Xiaona HeDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Shang ZhuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Xintian XuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Bin LiuCollege of Biology, Hunan University, Changsha, 410082, China.
Lihong LiuDepartment of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. drliulh@csu.edu.cn.ORCID http://orcid.org/0000-0002-2923-3014

Funding

the Hunan Provincial Basic Education Teaching Reform Research Project Y2024898the Hunan Provincial College Students' Innovation and Entrepreneurship Training Program S202510533421the Hunan Provincial Natural Science Foundation 2022JJ40698the Innovation Training Program for College Students, Central South University X202510533658the National Natural Science Foundation of China 82171581the National Undergraduate Innovation and Entrepreneurship Training Program S202410533139the Research Project on Education and Teaching Reform, Central South University 2023jy100
6 · The paper itself

Abstract

Senile osteoporosis (SOP) is a chronic age-related skeletal disorder characterized by progressive bone loss and high fracture risk, with pathogenesis linked to excessive reactive oxygen species (ROS), osteoprogenitor cell senescence, and macrophage inflammation. Prussian Blue (PB) nanozymes show antioxidative potential for SOP but are limited by poor targeting, short circulation time, and unclear mechanisms, restricting clinical translation. Herein, we fabricated macrophage membrane-camouflaged citrate-modified PB (M@CPB) nanozymes for targeted SOP therapy and elucidated the underlying mechanism. Macrophage membrane coating prolonged the blood half-life of M@CPB by 1.47-fold and enhanced its bone tissue accumulation by 3.09-fold relative to CPB. In vitro, M@CPB inhibited O₂⁻ by 42.17% and scavenged H

Indexed as

Cellular SenescenceFerrocyanidesMacrophagesOsteoporosisAnimalsHumansInflammationMaleMiceMice, Inbred C57BLRANK LigandRAW 264.7 CellsReactive Oxygen SpeciesTumor Necrosis Factor-alphaferric ferrocyanideFerrocyanidesRANK LigandReactive Oxygen SpeciesTumor Necrosis Factor-alphaCellular senescenceChronic inflammationPrussian blue nanozymeReactive oxygen speciesSenile osteoporosis

Identifiers

PMID42469812
PMCPMC13660348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.